| abstract |
This invention provides a combination of a hypoglycemic, metformin, and an irreversible intestinal gastric and pancreatic lipase inhibitor, Orlistat, for a better control of obesity than with the monotherapy used with each of them; this composition provides "low" doses of both drugs to minimize secondary effects and to make use of the synergic effect of both compounds. |